BRAF and melanoma: In both the 1205Lu BRAF‐mutant melanoma cell line and the WM1366 NRAS‐mutant melanoma cell line, treatment with dabrafenib, but not vemurafenib, led to abrogation of RB protein phosphorylation and strong upregulation of p27 (Fig. 6A).